Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of "Moderate Buy" by Analysts

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $40.13.

Several research firms have recently issued reports on BCYC. Stephens started coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They issued an "equal weight" rating and a $25.00 target price for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Royal Bank of Canada reiterated an "outperform" rating and set a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $48.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th.

Bicycle Therapeutics Stock Down 0.6 %

NASDAQ BCYC opened at $20.36 on Thursday. The business has a 50 day simple moving average of $24.37 and a 200 day simple moving average of $23.10. Bicycle Therapeutics has a one year low of $13.07 and a one year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the previous year, the business posted ($1.26) EPS. Bicycle Therapeutics's quarterly revenue was down 50.0% on a year-over-year basis. On average, equities analysts predict that Bicycle Therapeutics will post -3.07 EPS for the current year.

Insider Buying and Selling

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of the company's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the completion of the transaction, the chief accounting officer now owns 19,241 shares of the company's stock, valued at $483,141.51. This represents a 24.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin Lee sold 3,212 shares of the company's stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the transaction, the chief executive officer now owns 380,864 shares of the company's stock, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,840 shares of company stock worth $259,128 in the last ninety days. 8.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors have recently added to or reduced their stakes in BCYC. Baker BROS. Advisors LP lifted its holdings in shares of Bicycle Therapeutics by 176.1% during the first quarter. Baker BROS. Advisors LP now owns 4,942,823 shares of the company's stock valued at $123,076,000 after purchasing an additional 3,152,433 shares during the last quarter. Armistice Capital LLC increased its holdings in shares of Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company's stock valued at $39,913,000 after acquiring an additional 300,000 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of Bicycle Therapeutics by 21.5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock worth $41,887,000 after purchasing an additional 327,089 shares during the last quarter. First Light Asset Management LLC boosted its stake in Bicycle Therapeutics by 16.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company's stock worth $28,028,000 after purchasing an additional 191,717 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company's stock valued at $20,362,000 after purchasing an additional 841,299 shares in the last quarter. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.